DeepMed Research

Loxapine

Generic Name: Loxapine

Brand Names: Adasuve, Xylac

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₈ClN_₃O

CAS Number: 1977-10-2

Unique Ingredient Identifier: LER583670J

Background: An antipsychotic agent used in schizophrenia. [PubChem]

Indication: For the management of the manifestations of psychotic disorders such as schizophrenia

Associated Conditions: Acute Agitation, Schizophrenia

Clinical Trials

AGItated Patients Management: intraNASAL Midazolam vs Intramuscular Loxapine

Phase 3

Terminated

Conditions: Emergence Delirium

Interventions: Drug: Intranasal midazolam
Drug: Intramuscular loxapine

First Posted Date: 2022-04-12

Last Posted Date: 2024-05-28

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 1

Registration Number: NCT05324852

Locations: 🇫🇷
Hôpital Avicenne, Bobigny, France

A Study of Staccato Loxapine (ADASUVE®) for Inhalation

Phase 3

Conditions: Psychomotor Agitation
Schizophrenia
Bipolar Disorder

Interventions: Drug: Inhaled loxapine
Drug: Inhaled placebo

First Posted Date: 2019-11-04

Last Posted Date: 2019-11-05

Lead Sponsor: Lee's Pharmaceutical Limited

Target Recruit Count: 150

Registration Number: NCT04148963

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Conditions: Agitation,Psychomotor

Interventions: Drug: Loxapine 10 MG

First Posted Date: 2018-05-01

Last Posted Date: 2020-10-19

Lead Sponsor: Alexza Pharmaceuticals, Inc.

Target Recruit Count: 10000

Registration Number: NCT03513549

Locations: 🇺🇸
Pharmaceutical Research Associates, Inc, Raleigh, North Carolina, United States

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation

Phase 4

Terminated

Conditions: Haloperidol Causing Adverse Effects in Therapeutic Use
Loxapine Causing Adverse Effects in Therapeutic Use
Agitation,Psychomotor
Lorazepam Causing Adverse Effects in Therapeutic Use

Interventions: Drug: Loxapine
Drug: Haloperidol + lorazepam

First Posted Date: 2017-04-12

Last Posted Date: 2018-06-11

Lead Sponsor: University of Arkansas

Target Recruit Count: 2

Registration Number: NCT03110900

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Tolerability and Analgesic Efficacy of Loxapine in Patients With Refractory, Chemotherapy-induced Neuropathic Pain

Phase 2

Terminated

Conditions: Neuropathic Pain

Interventions: Drug: Loxapine

First Posted Date: 2016-07-01

Last Posted Date: 2022-07-01

Lead Sponsor: University of Witten/Herdecke

Target Recruit Count: 4

Registration Number: NCT02820519

Locations: 🇩🇪
HELIOS Clinic Wuppertal, Wuppertal, NRW, Germany

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed

Conditions: Schizophrenia

Interventions: Other: Caregiver psycho-education and skills training
Other: Caregiver support available at the study site
Drug: Paliperidone palmitate
Drug: Chlorpromazine
Drug: Droperidol
Drug: Fluphenazine
Drug: Haloperidol
Drug: Loxapine
Drug: Perphenazine
Drug: Pimozide
Drug: Prochlorperazine
Drug: Thiothixene
Drug: Thioridazine
Drug: Trifluoperazine
Drug: Aripiprazole
Drug: Asenapine
Drug: Clozapine
Drug: Iloperidone
Drug: Olanzapine
Drug: Paliperidone
Drug: Quetiapine
Drug: Risperidone
Drug: Ziprasidone

First Posted Date: 2015-11-09

Last Posted Date: 2019-01-23

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 296

Registration Number: NCT02600741

Outcomes of Antipsychotic Medication Used in the Emergency Department

Completed

Conditions: Agitation,Psychomotor

First Posted Date: 2015-07-22

Last Posted Date: 2024-10-04

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 93

Registration Number: NCT02504450

Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

Phase 1

Completed

Conditions: BiPolar

Interventions: Drug: ADASUVE®

First Posted Date: 2014-07-09

Last Posted Date: 2021-11-12

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 30

Registration Number: NCT02184767

Locations: 🇺🇸
Teva Investigational Site 12468, Atlanta, Georgia, United States
🇺🇸
Teva Investigational Site 12469, Cincinnati, Ohio, United States

ADASUVE-Lorazepam Drug-Drug Interaction

Phase 4

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Lorazepam 1 mg IM
Drug: Inhaled loxapine 10 mg
Drug: Inhaled Placebo
Drug: Placebo IM

First Posted Date: 2013-06-14

Last Posted Date: 2017-12-13

Lead Sponsor: Alexza Pharmaceuticals, Inc.

Target Recruit Count: 22

Registration Number: NCT01877642

Locations: 🇺🇸
Covance-Evansville, Evansville, Indiana, United States

ADASUVE 2-dose Thorough QT/QTc Study

Phase 4

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ADASUVE 10 mg 2 doses 2 hours apart
Drug: Inhaled Placebo
Drug: Oral moxifloxacin 400 mg
Drug: Oral placebo

First Posted Date: 2013-05-15

Last Posted Date: 2017-10-18

Lead Sponsor: Alexza Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT01854710

Locations: 🇳🇱
PRA International, Zuidlaren, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy